NeuroMetrix Capex To Revenue vs Operating Cash Flow Per Share Analysis
NURO Stock | USD 4.25 0.03 0.71% |
NeuroMetrix financial indicator trend analysis is infinitely more than just investigating NeuroMetrix recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NeuroMetrix is a good investment. Please check the relationship between NeuroMetrix Capex To Revenue and its Operating Cash Flow Per Share accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.
Capex To Revenue vs Operating Cash Flow Per Share
Capex To Revenue vs Operating Cash Flow Per Share Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NeuroMetrix Capex To Revenue account and Operating Cash Flow Per Share. At this time, the significance of the direction appears to have very week relationship.
The correlation between NeuroMetrix's Capex To Revenue and Operating Cash Flow Per Share is 0.21. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Operating Cash Flow Per Share in the same time period over historical financial statements of NeuroMetrix, assuming nothing else is changed. The correlation between historical values of NeuroMetrix's Capex To Revenue and Operating Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of NeuroMetrix are associated (or correlated) with its Operating Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Cash Flow Per Share has no effect on the direction of Capex To Revenue i.e., NeuroMetrix's Capex To Revenue and Operating Cash Flow Per Share go up and down completely randomly.
Correlation Coefficient | 0.21 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Most indicators from NeuroMetrix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NeuroMetrix current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.As of the 27th of November 2024, Selling General Administrative is likely to drop to about 4.7 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 2.5 M
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 5.9M | 5.8M | 3.9M | 3.8M | Total Revenue | 8.3M | 8.3M | 5.9M | 5.6M |
NeuroMetrix fundamental ratios Correlations
Click cells to compare fundamentals
NeuroMetrix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NeuroMetrix fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 121.0K | 3.8M | 2.6M | 891.3K | 1.0M | 1.1M | |
Total Assets | 6.9M | 8.0M | 24.9M | 24.7M | 21.4M | 17.5M | |
Other Current Liab | 2.1M | 1.5M | 515.9K | 309.9K | 586.7K | 557.3K | |
Total Current Liabilities | 3.4M | 2.3M | 1.4M | 1.1M | 1.2M | 1.2M | |
Total Stockholder Equity | 2.5M | 5.2M | 23.2M | 23.4M | 20.1M | 14.4M | |
Property Plant And Equipment Net | 1.4M | 876.2K | 673.9K | 536.2K | 543.6K | 599.7K | |
Net Debt | (2.2M) | (4.8M) | (22.3M) | (3.9M) | (1.5M) | (1.6M) | |
Retained Earnings | (194.8M) | (196.9M) | (199.2M) | (203.6M) | (210.1M) | (220.6M) | |
Accounts Payable | 725.7K | 142.3K | 284.0K | 368.1K | 215.5K | 204.7K | |
Cash | 3.1M | 5.2M | 22.6M | 4.3M | 1.7M | 1.6M | |
Non Current Assets Total | 1.5M | 904.7K | 700.3K | 562.6K | 570.0K | 541.5K | |
Non Currrent Assets Other | 74.9K | 29.7K | 28.5K | 26.4K | 30.4K | 31.9K | |
Other Assets | 30.3K | 29.7K | 721.2K | 700.3K | 630.3K | 600.4K | |
Cash And Short Term Investments | 3.1M | 5.2M | 22.6M | 21.2M | 18.0M | 12.0M | |
Net Receivables | 488.0K | 334.3K | 310.8K | 646.8K | 518.8K | 492.9K | |
Common Stock Total Equity | 271.0 | 738.0 | 140.0 | 379.0 | 341.1 | 669.34 | |
Liabilities And Stockholders Equity | 6.9M | 8.0M | 24.9M | 24.7M | 21.4M | 17.5M | |
Non Current Liabilities Total | 916.7K | 461.4K | 306.7K | 207.5K | 92.5K | 87.9K | |
Inventory | 1.2M | 1.1M | 706.6K | 1.6M | 1.6M | 1.6M | |
Other Current Assets | 2.3M | 478.1K | 598.4K | 645.5K | 779.0K | 1.5M | |
Other Stockholder Equity | 197.3M | 202.1M | 222.4M | 226.9M | 230.0M | 241.5M | |
Total Liab | 4.4M | 2.7M | 1.7M | 1.3M | 1.3M | 1.3M | |
Property Plant And Equipment Gross | 1.4M | 183.5K | 2.0M | 1.2M | 1.3M | 926.1K | |
Total Current Assets | 5.4M | 7.1M | 24.2M | 24.1M | 20.9M | 15.7M | |
Accumulated Other Comprehensive Income | (1.1M) | (1.2M) | (1.2M) | 0.0 | 240.2K | 252.2K | |
Common Stock | 140.0 | 379.0 | 668.0 | 778.0 | 152.0 | 144.4 | |
Property Plant Equipment | 2.4M | 273.4K | 183.5K | 673.9K | 606.5K | 621.0K | |
Retained Earnings Total Equity | (191.3M) | (191.0M) | (194.8M) | (196.9M) | (177.2M) | (186.1M) | |
Net Tangible Assets | 6.1M | 2.5M | 5.2M | 23.2M | 26.7M | 28.0M | |
Capital Surpluse | 196.4M | 197.1M | 197.3M | 202.1M | 232.4M | 201.3M | |
Net Invested Capital | 2.5M | 5.2M | 23.2M | 23.4M | 20.1M | 13.4M | |
Net Working Capital | 2.0M | 4.8M | 22.8M | 23.0M | 19.6M | 12.9M | |
Capital Stock | 141.0 | 380.0 | 669.0 | 779.0 | 153.0 | 145.35 |
Pair Trading with NeuroMetrix
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeuroMetrix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeuroMetrix will appreciate offsetting losses from the drop in the long position's value.Moving against NeuroMetrix Stock
0.49 | LH | Laboratory | PairCorr |
0.45 | MOH | Molina Healthcare | PairCorr |
0.43 | HUM | Humana Inc Fiscal Year End 23rd of January 2025 | PairCorr |
0.34 | UNH | UnitedHealth Group Fiscal Year End 10th of January 2025 | PairCorr |
0.31 | XAIR | Beyond Air | PairCorr |
The ability to find closely correlated positions to NeuroMetrix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeuroMetrix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeuroMetrix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeuroMetrix to buy it.
The correlation of NeuroMetrix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeuroMetrix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeuroMetrix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeuroMetrix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroMetrix. If investors know NeuroMetrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroMetrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.51) | Revenue Per Share 2.157 | Quarterly Revenue Growth (0.51) | Return On Assets (0.28) | Return On Equity (0.43) |
The market value of NeuroMetrix is measured differently than its book value, which is the value of NeuroMetrix that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroMetrix's value that differs from its market value or its book value, called intrinsic value, which is NeuroMetrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroMetrix's market value can be influenced by many factors that don't directly affect NeuroMetrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuroMetrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuroMetrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroMetrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.